Vitamin D receptor polymorphisms in overweight/obese chronic kidney disease patients undergoing hemodialysis

Gokhan Bagci¹, Can Huzmeli², Ferhan Candan³

¹Department of Medical Genetics, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey

²Department of Nephrology, Hatay State Hospital, Hatay, Turkey

³Department of Nephrology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey

Running Title: VDR polymorphism in obese/overweight CKD patients

***Corresponding Author**

Gokhan Bagci, PhD.

Department of Medical Genetics

Faculty of Medicine, Sivas Cumhuriyet University,

58140, Sivas, Turkey

Phone: +90 346 258 10 87

e-mail: gokhanbagci@hotmail.com.tr

Abstract

Background: Many studies were carried out to investigate the relationship between single nucleotide polymorphisms (SNPs) in vitamin D receptor (VDR) gene with obesity. However, little is known about the role of VDR gene polymorphism with obesity in hemodialysis (HD) patients. Therefore, we aimed to investigate VDR gene TaqI, ApaI and FokI SNPs in overweight/obese HD patients.

Methods: Seventy one normal weight and 68 overweight/obese HD patients were included in study. PCR-RFLP method was used for genotyping. Demographic and laboratory data obtained from medical records of patients.

Results: For all three SNPs, no significant association was found between normal and overweight/obese patients ($P>0.05$). Lower HDL concentrations and higher levels of triglyceride (TG) and glucose were detected in the obese/overweight patients compared to normal weight ($p<0.001$ for HDL, and TG and $p=0.023$ for glucose). In obese/overweight patients, subjects with CC genotype of TaqI showed higher PTH level (717.1 ± 616.4 pg/ml) than those TC genotype (342.7 ± 360.8 pg/ml) and TT genotype (310.2 ± 323.4 pg/ml) ($p=0.028$); higher TG level was found in patients with CC genotype of ApaI (627.3 ± 653.0 mg/dl) compared to AA (223.3 ± 156.6) and AC genotypes (193.1 ± 85.4) ($p<0.001$). Obese/overweight patients carrying FokI TT genotype had higher glucose concentration compared to those carrying CC and CT genotypes (CC= 183.4 ± 128.4 mg/dl; TT= 151.9 ± 66.1 mg/dl; CT= 107.6 ± 41.9 mg/dl, $p=0.008$).

Conclusions: Our study suggest that VDR TaqI, ApaI and FokI polymorphisms are not associated with obesity in HD patients. However, they might be increase the risk of secondary hyperparathyroidism, dyslipidemia, and hyperglycemia, which are among the most common obesity related comorbidities of chronic kidney disease.

Introduction

Obesity is a chronic multifactorial disease in which genetic and environmental factors play a role. Obesity is associated with important diseases such as type 2 diabetes, cardiovascular disease (CVD), hypertension and cancer (1). It is a major public health problem affecting an important proportion of the world population. According to TURDEP-II study finished in 2010 (26,499 people were participated), the prevalence of obesity in Turkey is 36% and the prevalence of overweight is 37% (2). Obesity is a major risk factor for chronic kidney disease (CKD) and is a strong risk factor for the loss of kidney function after dialysis therapy is started (3).

Vitamin D or 1,25-dihydroxyvitamin D $1,25(\text{OH})_2\text{D}$ is a steroid pro-hormone mostly synthesized from UVB-induced 7-dehydrocholesterol in the skin. The fat-soluble cholecalciferol and ergocalciferol are metabolized to a more polar form, $25(\text{OH})\text{D}$, by the liver. $25(\text{OH})\text{D}$ is hydroxylated to the biologically active form $1,25(\text{OH})_2\text{D}$ with renal 1- α hydroxylase. Due to a longer half-life and a 1000-fold higher serum concentration, $25(\text{OH})\text{D}$ concentrations are predominantly used to indicate vitamin D deficiency (4).

Vitamin D receptor (VDR) is a nuclear receptor that binds to $1,25(\text{OH})_2\text{D}$ with high affinity. VDR forms a heterodimer with the retinoid X receptor and then binds to hormone response elements in the target genes (5). The effect of $1,25(\text{OH})_2\text{D}$ is mediated by VDR, which regulates the transcription of many target genes involved in various physiological processes (6, 7). VDR expression was detected in the majority of human tissues, including osteoblasts, smooth muscle cells, macrophages, epithelial cells and pancreatic β -cells, and its expression also highly found in adipocytes. Adipose tissue express both the VDR and the enzymes involved in vitamin D metabolism. VDR expression is reported in human subcutaneous adipose tissue and visceral adipose tissue (8-10).

Vitamin D deficiency is common in CKD patients. Various factors, including increased age and comorbid conditions, such as diabetes and hypertension, have been associated with lower $25(\text{OH})\text{D}$ levels in individuals with both dialysis-dependent and non-dialysis-dependent CKD (11). The main reason for progressive reduction of active vitamin D serum levels in CKD is the simultaneous decrease in renal 1α -hydroxylase levels with progressive decrease in renal mass and function. Furthermore, secondary hyperparathyroidism and hyperphosphoremia may contribute to the inhibition of vitamin D activation by the kidneys. Because of the complex role of vitamin D in CKD, some variants in the VDR gene have been considered as a way of improving the management of the disease since they are

thought to affect response to therapeutic approaches (12-13). It is thought that VDR gene polymorphisms may play a role in regulating adipose tissue activity, body fatness and susceptibility to adiposity (10).

Several studies have been performed to investigate VDR polymorphism in CKD patients with comorbidities such as secondary hyperparathyroidism (13), left ventricular hypertrophy (14) atherosclerosis (15), and type II diabetes (16). However, we did not find any study investigating the relationship between obesity and VDR gene polymorphisms in CKD patients. In the light of this information, we aimed to evaluate VDR gene polymorphisms in obese/overweight and non-obese/overweight CKD patients undergoing HD. A secondary objective was to investigate whether there is a relationship between VDR polymorphisms and demographic and biochemical data in obese/overweight HD patients.

Materials and methods

Subjects

For this cross-sectional study, we included a total of 139 HD patients, who have applied to the clinic in Department of Nephrology, Cumhuriyet University, and monitored in HD centers in Sivas City or its districts, were screened. According to body mass index (BMI) classification, patients with a BMI ≥ 25 and < 30 were assessed as having overweight, and ≥ 30 assessed as having obese. Patients with a BMI ≥ 18 and < 25 were assessed as having normal weight. According to this classification, 68 patients were considered obese or overweight, and 71 patients were considered normal weight. Demographic characteristics and routinely available laboratory data were extracted from the patients' medical files and from the electronic database of hospital. Patients with a BMI less than 18, patients with active infection or malignancy were excluded from the study.

Fasting blood specimens were collected to measure blood chemistry parameters. 25(OH)D, total cholesterol, triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL), C-reactive protein (CRP), creatinine, calcium, phosphorus, potassium, sodium, blood urea nitrogen (BUN), PTH, protein, albumin, glucose concentrations were measured by routine laboratory methods. Cholesterol to HDL ratio, TG to HDL ratio, and LDL to HDL ratio were calculated.

Genotyping

After sampling 5 ml of blood from the patients with K3DTA tubes, the samples were stored at -20 °C. The sampling was done using Genomic DNA QIAamp DNA Blood Mini Kit (QIAGEN, Germany).

Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method was used for genotyping. Primers used for PCR reaction were as follows: TaqI (rs731236) F: 5'-CAG AGC ATG GAC AGG GAG CAA G-3' and R: 5'-GCA ACTC CTC ATG GCT GAG GTC TCA-3', ApaI (rs7975232) F: 5' CAG AGC ATG GAC AGG GAG CAA G-3' and R: 5'-GCA ACT CCT CAT GGC TGA GGT CTC A-3', and FokI (rs2228570) F: 5'-AGC TGG CCC TGG CAC TGA CTC TTG CTC T-3' and R: 5'-ATG GAA ACA CCT TGC TTC TTC TCC CTC-3'. The PCR conditions were: denaturation at 94 °C for 15 s, annealing at 63 °C for TaqI and ApaI, and 65 °C for FokI for 30 s, and extension at 72 °C for 30 s for 35 cycles. Final extension at 72 °C for 7 min. PCR products were digested separately with restriction enzymes TaqI, ApaI and FokI (Thermo Fisher Scientific, Waltham, MA, USA). The digested products were analyzed by electrophoresis in a 2% agarose gel stained with ethidium bromide, and then evaluated at UV light.

Statistical Analysis

All statistical analyses of the study were performed by Statistical Package for the Social Sciences (SPSS) version 22.0 (SPSS IBM, New York, USA). Normally distributed continuous variables were expressed as mean $\pm$ standard deviation (SD), and non-normally distributed variables as medians and interquartile ranges (IQR; 25-75th percentiles). Student t-test or Mann-Whitney U test was used for group comparisons. Chi-Square test or Fisher's exact test was used for the evaluation of categorical values including genotype and allele frequencies of VDR SNPs. One-way ANOVA test was used to compare selected parameters in obese/overweight patients according to genotypes of TaqI, ApaI and FokI SNPs. Statistical significance was defined as P value less than 0.05. Results were expressed with a 95% confidence interval.

Results

In the present study, we evaluated VDR gene polymorphisms in 68 obese/overweight and 71 normal weight CKD patients undergoing HD and we investigated whether there is a relationship between VDR gene polymorphisms and demographic and biochemical data in obese/overweight HD patients. Demographic and biochemical data of patients are shown in Table 1. As expected, height, weight and BMI was significantly different in the two groups ($p = 0.028$ for height, $p < 0.001$ for weight and BMI). The frequency of women in obese/overweight patients was higher than normal weight patients (67.6% to 43.7%, $p = 0.004$). 52.9% of the patients in the obese/overweight group were diabetes mellitus and 22.5%

of the patients in the normal weight group were diabetes mellitus. Lower HDL concentrations and higher levels of TG and glucose were detected in the obese/overweight patients ($p < 0.001$ for HDL and TG and $p = 0.023$ or glucose). There were no statistically significant differences between the groups in terms of other demographic parameters and laboratory findings.

Table 2 show that genotype and allele frequencies of VDR gene SNPs in obese/overweight and normal weight patients. For all three SNPs, no significant difference was found between normal and overweight/obese patients ($p > 0.05$). Table 3 demonstrates that comparisons of some selected parameters according to TaqI, ApaI and FokI genotypes of VDR gene in overweight/obese patients. The genotypes of TaqI SNP of VDR gene did not show any significant differences in all selected parameters except from PTH level. The CC genotype of the TaqI VDR showed higher PTH level (717.1 ± 616.4 pg/ml) than the TC genotype (342.7 ± 360.8 pg/ml) and the TT genotype (310.2 ± 323.4 pg/ml) ($p = 0.028$). The genotypes of ApaI-VDR did not show any statistically significant differences in all selected parameters except from TG level and TG to HDL ratio. Higher TG level was found in the CC genotype of the ApaI-VDR (627.3 ± 653.0 mg/dl) compared to AA (223.3 ± 156.6) and AC genotypes (193.1 ± 85.4) ($p < 0.001$). Similarly, higher TG to HDL ratio was found in the ApaI CC genotype (25.3 ± 26.1) compared to the AA genotype (8.4 ± 7.1) and the AC genotype (7.1 ± 4.8). There were no significant differences in the selected parameters among the three genotypes of the FokI SNP except for glucose level. Obese/overweight patients carrying FokI TT genotype had higher glucose concentration compared to CC and CT genotypes (CC: 183.4 ± 128.4 ; TT: 151.9 ± 66.1 ; CT: 107.6 ± 41.9 , $p = 0.008$).

Discussion

Adipose tissue is an organ which has important metabolic functions. It plays an important role in energy balance and glucose hemostasis. It is also known as the main storage source for vitamin D (17). Obesity is caused by the imbalance between energy intake and expenditure. Obese people have increased body fat mass (adipocyte hyperplasia and hypertrophy). Obesity, an outbreak of the 21st century, is an increased risk factor for comorbid complications such as CVD, hypertension, dyslipidemia, type 2 diabetes and cancer. In addition, obesity increases the risk of CKD and its progression to end stage renal disease (18). Obesity and diabetes mellitus are very common in HD patients. It has been suggested that an association was found between vitamin D deficiency and obesity (3).

The relationship between vitamin D deficiency and obesity is explained in various ways: i) Obese individuals have reduced exposure to the sun compared to the weak, ii)

Vitamin D is sequestered in fat tissue, iii) Low 1,25(OH)₂D inhibits adipogenesis, iv) Low 25(OH)D concentration is just due to volumetric dilution (17-19). It has been suggested that vitamin D is associated with dyslipidemia (20). The administration of 1,25(OH)₂D significantly increases the calcium (Ca⁺²) transport into the adipose tissue and thereafter lipogenesis is induced and lipolysis is reduced (21). In addition, 1,25(OH)₂D can stop the production of uncoupling protein (UCP2) by accelerating the Ca⁺² flow into the cell, and thus it has the effect of increasing obesity (22).

In Turkey, vitamin D deficiency and insufficiency have been commonly detected in overweight and obese individuals, especially in women and there was a negative correlation between vitamin D level and obesity (24). González et al. (25) found significantly lower vitamin D levels in individuals with high BMI, waist circumference (WC), and waist-to-height ratio. Saneii et al. (26) included 34 studies in the meta-analysis, they reported that a significant inverse weak correlation between BMI and serum 25(OH)D levels. Pereira-Santos et al. (27) included 23 studies in the meta-analysis, they found that obese subjects had 35% vitamin D deficiency compared to those with normal weight and 24% higher than in the overweight group. In another meta-analysis, Yao et al. (28) reported that vitamin D deficiency was prevalently associated with obesity in European-Americans and Asians. The prevalence of vitamin D deficiency is higher among the CKD, diabetes and obesity patients in the groups which are major risk factors for vitamin D deficiency (29).

VDR is present on adipocytes and many studies have been carried out to examine the relationship between VDR gene polymorphisms and obesity. In a study with Pakistani patients, no significant relationship was found between VDR FokI SNP and obesity (30). In a study with obese women, vitamin D deficiency and insufficiency were detected in 80.3% of the subjects. No significant difference was found between the two groups in terms of ApaI polymorphism. (31). In Chinese population, the TT genotype and the T allele of TaqI SNP is found to be associated with obesity (32). A study in the Greek population showed that TaqI T allele associated with higher BMI (33). In another study, ApaI and TaqI SNP of the VDR gene were examined in patients with diabetes mellitus. No significant difference has been shown between patients and controls. However, in subjects with early-onset T2DM, a higher BMI and an increased prevalence of obesity (81%) was found in subjects carrying TT genotype of the TaqI compared to TC (46%) or tt (52%) genotypes (34). In the 1958 British birth cohort study (1958BC) which was conducted with 5,224 participants, VDR SNPs were not associated with obesity traits (35). In a cross-sectional study of 198 Arab adults, the TT carriers of FokI SNP had higher total cholesterol than that of CC and CT genotypes (36). In a

recent study conducted with 402 obese and 489 non-obese Saudis, VDR TaqI minor allele polymorphisms were found more frequent in obese individuals (37).

In the current study, lower HDL and higher TG concentrations were detected in obese/overweight HD patients compared to non-obese/overweight patients. In a study conducted in obese children, a positive correlation was found between serum 25(OH)D concentration and HDL, while a negative correlation was found between TG (14). In a study of 1534 individuals, a positive correlation was found between vitamin D, HDL and age. A negative correlation was found between vitamin D and BMI, LDL, cholesterol and TG (38). NHANES III trial demonstrated negative association between serum 25(OH)D levels and hypertriglyceridemia, diabetes, hypertension, and obesity (39). In children with obesity and metabolic syndrome, vitamin D supplementation did not affect total cholesterol, LDL and HDL levels, but TG levels decreased (40). Jorde et al. (41) included 12 cross-sectional and 10 placebo-controlled intervention studies in the meta-analysis, they found a positive correlation between serum 25(OH)D level and HDL and a negative correlation with TG in the majority of studies. On the other hand, recent randomized clinical trials evaluating the effect of vitamin D supplementation on blood lipids have reported conflicting evidences. In the majority of studies, it has been found that vitamin D supplementation is not a significant effect on blood lipids compared to placebo (42-44). These recent findings make it difficult to decide whether there is a causal relationship between vitamin D deficiency and a negative blood lipid profile.

In the present study, glucose concentration was higher in the obese/overweight group. This may be due to the high number of patients with diabetes mellitus in the obese/overweight group. 1,25(OH)₂D is an important regulator of insulin release from pancreas (45). In 1,25(OH)₂D deficient animals, intravenous 1,25(OH)₂D administration improves glucose intolerance and induces insulin releasing from beta cells of pancreas in response to a glucose challenge (46). In a study involving 120 non-diabetic CKD patients, obese patients treated with 1,25(OH)₂D had similar insulin concentrations compared to non-obese patients, whereas untreated obese patients had a higher insulin concentration (47). In our study, obese/overweight patients carrying FokI homozygous mutant TT genotype had higher glucose concentrations compared to those having CC and CT genotypes. In another study, individuals with FokI TT genotype was associated with higher HOMA-IR values than individuals with CT genotype. Thus, VDR FokI polymorphism has suggested to be associated with diabetes mellitus (48).

It has been suggested that there was a potential association between parathyroid function and VDR polymorphisms in CKD patients (13). In the current study, significantly

higher PTH levels were found in obese/overweight patients carrying TaqI CC genotype compared to those carrying TT and TC genotypes. In Iranian HD patients, similar findings were found in terms of TaqI variants (49). It has been suggested that the TaqI TT genotype increases the risk of development of hyperparathyroidism in Turkish HD patients (13).

The main limitation of the current study is the relatively small sample size. Further, we only calculated BMI for evaluation of obesity. We did not measure waist to hip ratio and waist circumference for evaluation of obesity.

In conclusion, our study shows that VDR gene TaqI, ApaI and FokI genotype and allele frequencies are not different in obese/overweight HD patients compared to normal weight patients. However, in obese/overweight HD patients, individuals carrying TaqI CC genotype have higher PTH levels, those carrying ApaI CC genotype have higher TG levels and those carrying FokI TT genotype have higher glucose levels. Although this study has shown that VDR polymorphisms are not related to obesity susceptibility, in overweight/obese HD patients, VDR polymorphisms have been suggested to increase the risk of secondary hyperparathyroidism, dyslipidemia, and hyperglycemia, which are among the most common obesity related comorbidities of CKD. Further studies are required to reveal any possible association between VDR polymorphisms and obesity in HD patients.

Compliance with ethical standards

Conflict of interest All of the authors of the current study declare that they have no conflict of interest.

Ethical approval Local ethics committee approval was obtained from Clinical Research Ethics Committee of Sivas Cumhuriyet University, Sivas, Turkey. All procedures performed in the current study have been performed in accordance with the ethical standards of the 1964 Helsinki Declaration and subsequent amendments or comparable ethical standards.

Informed consent All patients gave a written informed consent to participate in the current study.

References

1. Kienreich K, Tomaschitz A, Verheyen N, Pieber T, Gaksch M, Gröbler MR, Pilz S. Vitamin D and cardiovascular disease. *Nutrients*. 2013;5(8):3005-21.
2. Satman I, Omer B, Tutuncu Y, Kalaca S, Gedik S, Dinccag N, Karsidag K, Genc S, Telci A, Canbaz B, Turker F, Yilmaz T, Cakir B, Tuomilehto J; TURDEP-II Study Group. Twelve-

year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. *Eur J Epidemiol.* 2013;28(2):169-80.

3. Chertow GM, Hsu CY, Johansen KL. The enlarging body of evidence: Obesity and chronic kidney disease. *J Am Soc Nephrol* 2006;17:1501-2,

4. Wacker M, Holick MF. Vitamin D—Effects on skeletal and extraskeletal health and the need for supplementation. *Nutrients.* 2013;5:111-48.

5. Bikle D. Nonclassic actions of vitamin D. *J Clin Endocrinol Metabol.* 2009;94(1):26-34.

6. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. *Endocrinology.* 2006;147:5542–5548.

7. Plum LA, DeLuca HF. Vitamin D, disease and therapeutic opportunities. *Nat Rev Drug Discov.* 2010;9:941–955.

8. Ching S, Kashinkunti S, Niehaus MD, Zinser GM. Mammary adipocytes bioactivate 25-hydroxyvitamin D and signal via vitamin D receptor, modulating mammary epithelial cell growth, *J Cell Biochem.* 2011;112:3393-405.

9. Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. *Br J Nutr.* 2012;108:1915-23.

10. Ochs-Balcom HM, Chennamaneni R, Millen AE, Shields PG, Marian C, Trevisan M, Freudenheim JL. Vitamin D receptor gene polymorphisms are associated with adiposity phenotypes. *Am J Clin Nutr.* 2011;93(1):5-10.

11. Echida Y, Mochizuki T, Uchida K, Tsuchiya K, Nitta K. Risk factors for vitamin D deficiency in patients with chronic kidney disease. *Intern Med.* 2012;51(8):845-50.

12. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R Vitamin D levels and early mortality among incident hemodialysis patients. *Kidney Int.* 2007;72(8):1004-13.

13. Ozdemir FN, Sezer S, Atac B, Tural E, Verdi H, Sahin F, Haberal M. Vitamin D receptor BsmI and TaqI gene polymorphisms in a Turkish ESRD population: influences on parathyroid hormone response. *Transplant Proc.* 2005;37(7):2922-4.

14. Santoro D, Gagliostro G, Alibrandi A, Ientile R, Bellinghieri G, Savica V, Buemi M, Caccamo D. Vitamin D receptor gene polymorphism and left ventricular hypertrophy in chronic kidney disease. *Nutrients.* 2014;6(3):1029-37.

15. El-Shehaby AM, El-Khatib MM, Marzouk S, Battah AA. Relationship of BsmI polymorphism of vitamin D receptor gene with left ventricular hypertrophy and atherosclerosis in hemodialysis patients. *Scand J Clin Lab Invest.* 2013;73(1):75-81.

16. Yokoyama K, Nakashima A, Urashima M, Suga H, Mimura T, Kimura Y, Kanazawa Y, Yokota T, Sakamoto M, Ishizawa S, Nishimura R, Kurata H, Tanno Y, Tojo K, Kageyama S, Ohkido I, Utsunomiya K, Hosoya T. Interactions between serum vitamin D levels and vitamin D receptor gene FokI polymorphisms for renal function in patients with type 2 diabetes. *PLoS One*. 2012;7(12):e51171.
17. Wamberg L, Christiansen T, Paulsen SK, Fisker S, Rask P, Rejnmark L, Richelsen B, Pedersen SB. Expression of vitamin D-metabolizing enzymes in human adipose tissue -- the effect of obesity and diet-induced weight loss. *Int J Obes (Lond)*. 2013;37(5):651-7.
18. Lucisano S, Buemi M, Passantino A, Aloisi C, Cernaro V, Santoro D. New insights on the role of vitamin D in the progression of renal damage. *Kidney Blood Press Res*. 2013;37(6):667-78.
19. Drincic AT, Armas LA, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. *Obesity (Silver Spring)*. 2012;20(7):1444-8.
20. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr*. 2000;72:690-693.
21. Kim M, Na W, Sohn C. Correlation between vitamin D and cardiovascular disease predictors in overweight and obese Koreans. *J Clin Biochem Nutr*. 2013; 52(2): 167-71.
22. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha,25-Dihydroxyvitamin D3 modulates human adipocyte metabolism via nongenomic action. *FASEB J*. 2001;15(14):2751-3.
23. Shi H, Norman AW, Okamura WH, Sen A, Zemel MB. 1alpha,25-dihydroxyvitamin D3 inhibits uncoupling protein 2 expression in human adipocytes. *FASEB J*. 2002;16(13):1808-10.
24. Aypak C, Yikilkan H, Dicle M, Onder O, Gorpelioglu S. The relationship of vitamin D status with body mass index among obese adults. *The Medical Bulletin of Haseki* 2013;51(3): 95-99.
25. González L, Ramos-Trautmann G, Díaz-Luquis GM, Pérez CM, Palacios C. Vitamin D status is inversely associated with obesity in a clinic-based sample in Puerto Rico. *Nutr Res*. 2015;35(4):287-293.
26. Saneei P, Salehi-Abargouei A, Esmailzadeh A. Serum 25-hydroxy vitamin D levels in relation to body mass index: a systematic review and meta-analysis. *Obes Rev*. 2013;14:393–404.

27. Pereira-Santos M, Costa PR, Assis AM, Santos CA, Santos DB. Obesity and vitamin D deficiency: a systematic review and meta-analysis. *Obes Rev.* 2015;16:341–349.
28. Yao Y, Zhu L, He L, Duan Y, Liang W, Nie Z, Jin Y, Wu X, Fang Y. A meta-analysis of the relationship between vitamin D deficiency and obesity. *Int J Clin Exp Med.* 2015;8(9):14977-84.
29. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. *J Am Soc Nephrol.* 2009;20(12):2631-9.
30. Haris Lucky M, Baig S. The Vitamin D Receptor (VDR) Gene Polymorphisms Fok1 In Obese Pakistanis– a Preliminary Report. *Int J Adv Biol Biom Res.* 2014;2(9):2569-74.
31. Sharif E, Swaidan N, Shurbaji S, Rizk NM. Associations of Vitamin D Receptor Polymorphism rs1544410 with Adiposity Phenotypes. *Endocrinol Metab Int J.* 2016;3(6):00069.
32. Fan HR, Lin LQ, Ma H, Li Y, Sun CH. Association between vitamin D receptor gene polymorphism (TaqI) and obesity in Chinese population. *J Genet.* 2015;94(3):473-8.
33. Vasilopoulos Y, Sarafidou T, Kotsa K, Papadimitriou M, Goutzelas Y, Stamatis C, Bagiatis V, Tsekmekidou X, Yovos JG, Mamuris Z. VDR TaqI is associated with obesity in the Greek population. *Gene.* 2013;512(2):237-9.
34. Ye WZ, Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, Timsit J, Velho G. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. *Eur J Endocrinol.* 2001;145(2):181-6.
35. Vimalaswaran KS, Cavadino A, Berry DJ, Whittaker JC, Power C, Järvelin MR, Hyppönen E. Genetic association analysis of vitamin D pathway with obesity traits. *Int J Obes (Lond).* 2013;37(10):1399-406.
36. Hasan HA, AbuOdeh RO, Muda WA, Mohamed HJ, Samsudin AR. Association of Vitamin D receptor gene polymorphisms with metabolic syndrome and its components among adult Arabs from the United Arab Emirates. *Diabetes Metab Syndr.* 2017. doi: 10.1016/j.dsx.2017.03.047.
37. Al-Daghri NM, Guerini FR, Al-Attas OS, Alokail MS, Alkharfy KM, Draz HM, Agliardi C, Costa AS, Saulle I, Mohammed AK, Biasin M, Clerici M. Vitamin D receptor gene polymorphisms are associated with obesity and inflammasome activity. *PLoS One.* 2014;9(7):e102141.

38. Glueck CJ, Jetty V, Rothschild M, Duhon G, Shah P, Prince M, Lee K, Goldenberg M, Kumar A, Goldenberg N, Wang P. Associations between Serum 25-hydroxyvitamin D and Lipids, Lipoprotein Cholesterols, and Homocysteine. *N Am J Med Sci*. 2016;8(7):284-90.
39. Martins D, Wolf M, Pan D, Zadshir A, Tareen N, Thadhani R, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. *Arch Intern Med*. 2007;167(11):1159–65.
40. Kelishadi R, Salek S, Salek M, Hashemipour M, Movahedian M. Effects of vitamin D supplementation on insulin resistance and cardiometabolic risk factors in children with metabolic syndrome: a triple-masked controlled trial. *J Pediatr (Rio J)*, 2014; 90(1): 28-34.
41. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. *Prog Lipid Res* 2011;50(4):303-12.
42. Ponda MP, Dowd K, Finkelstein D, Holt PR, Breslow JL. The short-term effects of vitamin D repletion on cholesterol: a randomized, placebo-controlled trial. *Arterioscler Thromb Vasc Biol*. 2012;32(10):2510-5.
43. Ponda MP, Huang X, Odeh MA, Breslow JL, Kaufman HW. Vitamin D may not improve lipid levels: a serial clinical laboratory data study. *Circulation*. 2012;126(3):270-7.
44. Salehpour A, Shidfar F, Hosseiniapanah F, Vafa M, Razaghi M, Hoshirrad A, Gohari M. Vitamin D3 and the risk of CVD in overweight and obese women: a randomised controlled trial. *Br J Nutr*. 2012;108(10):1866-73.
45. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. *Kidney Int* 1998;53(5):1353-7.
46. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. *Endocrinology*. 1986;119(1):84-90
47. Friedman DJ, Bhatt N, Hayman NS, Nichols BJ, Herman M, Nikolaev N, Danziger J. Impact of activated vitamin D on insulin resistance in nondiabetic chronic kidney disease patients. *Clin Endocrinol (Oxf)*. 2012;77(1):56-61
48. Angela B, Leraa L, Sáncheza H, Oyarzún A, Albalaa C. FokI polymorphism in vitamin D receptor gene: Differential expression of TNF α in peripheral mononuclear cells of type 2 diabetic subjects. *Meta Gene*. 2016;7:1–6
49. Pourfarzam M, Nia KM, Atapour A, Sadeghi HM. The influence of BsmI and TaqI vitamin D receptor gene polymorphisms on the intensity of hyperparathyroidism in Iranian hemodialysis patients. *Adv Biomed Res*. 2014;3:213.

Table 1. Baseline characteristics of obese/overweight and non-obese/overweight hemodialysis patients

Characteristic	Overall (N = 139)	Obese / overweight (N = 68)	Normal weight (N = 71)	P
Age (years)	58.6 ± 14.1	60.5 ± 10.3	56.8 ± 16.8	0.125
Sex (M/F) %	44.6 / 55.4	32.4 / 67.6	56.3 / 43.7	0.004
Height (cm)	165 (160-170)	163 (159-167)	168 (160-170)	0.028
Weight (kg)	68.8 ± 13.2	78.3 ± 11.1	59.6 ± 7.2	<0.001
BMI (kg/m ²)	24.8 (21.3-28.3)	28.4 (26.8-31.5)	21.5 (20.4-23.5)	<0.001
Smoking (%)	15 (10.8)	5 (9.1)	10 (16.7)	0.177
Duration of dialysis (months)	48 (27-96)	54 (24-94)	42 (27-96)	0.657
Diabetes mellitus (n, %)	52 (37.4)	36 (52.9)	16 (22.5)	<0.001
Hypertension (n, %)	25 (18)	13 (19.1)	12 (16.9)	0.733
25(OH)D (ng/mL)	10.4 (7.9-13.7)	10.3 (7.8-14.9)	10.8 (8.1-12.9)	0.757
Cholesterol (mg/dL)	165 (139-206)	183 (139-213)	160 (139-200)	0.114
TG (mg/dL)	156 (109-239)	191 (133-274)	133 (87-184)	<0.001
HDL (mg/dL)	34 (27-40)	31 (25-37)	37 (29-46)	<0.001
LDL (mg/dL)	99 (73-136)	110.5 (77-145)	96 (72-125)	0.112
CRP (mg/L)	9.8 (2.8-29)	10.5 (3.9-40)	6.7 (2.1-21)	0.119
Creatinine (mg/dL)	7.2 (6.0-9.6)	7.5 (6.3-9.7)	6.9 (5.6-9.6)	0.454
Calcium (mg/dL)	8.7 (8.2-9.1)	8.6 (8.3-9.1)	8.7 (8.2-9.2)	0.939
Phosphorus (mg/dL)	4.4 (3.6-5.4)	4.6 (3.7-5.4)	4.2 (3.6-5.5)	0.499
Potassium (mEq/L)	5.2 (4.4-5.7)	5.2 (4.5-5.7)	5.1 (4.4-5.9)	0.938
Sodium (mEq/L)	138 (135-140)	138 (137-140)	138 (136-140)	0.314
BUN (mg/dL)	64.5 ± 18.3	63.7 ± 16.8	65.2 ± 19.8	0.647
PTH (pg/ml)	255 (120-488)	238 (127-470)	262 (109-513)	0.583
Protein (g/dL)	6.8 (6.5-7.2)	6.9 (6.5-7.3)	6.8 (6.4-7.0)	0.066
Albumin (g/dL)	3.9 (3.6-4.2)	3.8 (3.6-4.2)	3.9 (3.7-4.2)	0.299
Glucose (mg/dL)	105 (86-147)	116 (90-155)	100 (84-121)	0.023
EPO use (n, %)	92 (66.2)	46 (67.6)	46 (64.8)	0.858
Calcitriol use (n, %)	49 (35.3)	24 (35.3)	25 (35.2)	0.992
Calcium use (n, %)	85 (61.2)	42 (61.8)	43 (60.6)	0.885

Data were expressed as mean ± SD, median and interquartile range, or as frequency and percent, as appropriate.

Table 2. Genotype and allele frequencies of VDR gene SNPs in obese/overweight and normal weight hemodialysis patients

SNP genotype/allele	Obese / overweight (N = 68)	Non obese / overweight (N = 71)	OR (95% CI)	P value
TaqI TT	32 (47.1)	30 (42.3)	Reference	-
TC	28 (41.2)	25 (35.2)	1.05 (0.50-2.18)	0.89
CC	8 (11.8)	16 (22.5)	0.46 (0.17-1.25)	0.13
T	0.676	0.598	Reference	-
C	0.324	0.402	0.71 (0.43-1.16)	0.17
ApaI AA	31 (45.6)	35 (49.3)	Reference	-
AC	34 (50.0)	31 (43.7)	1.19 (0.60-2.37)	0.60
CC	3 (4.4)	5 (7.0)	0.67 (0.14-3.06)	0.61
A	0.695	0.709	Reference	-
C	0.305	0.291	1.01 (0.60-1.70)	0.95
FokI CC	34 (50.0)	30 (42.3)	Reference	-
CT	27 (39.7)	35 (49.3)	0.68 (0.33-1.37)	0.28
TT	7 (10.3)	6 (8.5)	1.02 (0.31-3.40)	0.96
C	0.698	0.669	Reference	-
T	0.302	0.331	0.87 (0.52-1.44)	0.59

VDR: vitamin D receptor; SNP: single nucleotide polymorphism; OR: Odds Ratio; CI: confidence interval

Table 3. Comparisons of some selected parameters according to VDR gene TaqI, ApaI and FokI genotypes in obese/overweight patients.

	TaqI				ApaI				FokI			
Parameter	TT	TC	CC	P	AA	AC	CC	P	CC	CT	TT	P
BMI (kg/m ²)	29.1(3.4)	30.0(4.6)	29.7(4.1)	.70	29.3(3.4)	29.9(4.6)	27.8(1.8)	.62	29.4(4.5)	29.5(3.6)	30.6(3.2)	.74
25(OH)D (ng/ml)	11.3(4.3)	11.4(6.0)	11.8(5.0)	.47	10.9(3.9)	11.4(4.5)	16.8(4.4)	.08	11.3(4.2)	11.7(4.5)	11.3(4.9)	.93
Cholesterol (mg/dl)	176.9(55.1)	181.3(44.2)	154.6(53.4)	.17	182.6(56.2)	187.3(64.8)	137.7(33.0)	.39	188.6(61.7)	174.9(63.8)	185.7(39.0)	.69
TG (mg/d)	210.2(195.8)	183.4(103.8)	166.9(86.8)	.81	223.3(156.6)	193.1(85.4)	627.3(653.0)	<.001	224.4(138.6)	246.7(252.9)	198.1(78.3)	.80
HDL (mg/dl)	33.9(10.2)	36.7(14.0)	34.8(12.4)	.67	32.3(10.4)	31.3(9.1)	25.3(3.5)	.48	31.7(10.3)	30.7(8.4)	33.1(11.0)	.82
LDL (mg/dl)	138.0(137.6)	112.5(48.7)	108.1(38.4)	.56	134.6(137.3)	116.7(51.9)	96.7(65.2)	.69	142.0(130.5)	103.0(54.5)	117.7(37.7)	.32
Cholesterol/HDL	6.0(1.9)	6.5(2.1)	5.2(2.3)	.28	6.0(2.3)	6.2(2.0)	5.4(1.1)	.76	6.4(2.5)	5.7(1.6)	5.9(1.3)	.42
TG/HDL	8.9(10.2)	8.4(6.7)	7.3(3.2)	.88	8.4(7.1)	7.1(4.8)	25.3(26.1)	.001	8.4(6.5)	9.0(10.8)	7.0(4.4)	.84
LDL/HDL	4.6(5.9)	3.6(1.3)	3.8(1.0)	.62	4.5(6.0)	3.8(1.2)	3.7(2.0)	.74	3.0(1.4)	2.9(1.3)	2.1(0.7)	.31
Creatinine (mg/dl)	7.8(2.5)	8.0(2.9)	8.4(1.6)	.83	7.8(2.6)	8.1(2.6)	7.3(2.8)	.79	7.4(2.5)	8.4(2.5)	8.5(2.8)	.29
Calcium (mg/dl)	8.7(0.8)	8.5(0.7)	8.6(0.5)	.52	8.7(0.8)	8.5(0.7)	9.3(0.8)	.18	8.4(0.9)	8.8(0.8)	8.6(1.3)	.85
Phosphorus (mg/dl)	4.8(1.3)	4.3(1.4)	4.8(1.1)	.34	4.6(1.3)	4.6(1.4)	4.3(1.2)	.90	4.6(1.2)	4.6(1.6)	4.3(1.0)	.79
BUN (mg/dl)	67.0(14.0)	61.7(19.0)	58.1(18.4)	.29	67.0(18.2)	60.8(15.6)	64(14.8)	.34	60.3(15.9)	65.4(17.0)	74.3(17.2)	.11
PTH (pg/ml)	310.2(323.4)	342.7(360.8)	717.1(616.4)	.028	480.0(481.0)	286.2(298.3)	261.7(22.7)	.13	258.9(221.3)	489.3(534.7)	484.7(350.6)	.06
Glucose (mg/dl)	133.8(54.9)	138.6(78.8)	148.8(101.5)	.86	133.2(83.8)	139.2(60.0)	163.7(33.6)	.76	151.9(66.1)	107.6(41.9)	183.4(128.4)	.008